AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)
49.23 USD
+1.380 2.884%| Previous Close (in USD) | 47.85 |
|---|---|
| Change | +1.380 2.884% |
| 52 W H/L (in USD) | 22.090/13.560 |
| EBITDA (in USD) | -28.331M |
| PE Ratio | 146.46 |
| Volume | 470215 |
| Diluted Eps TTM | 0.13 |
| Total Assets (in USD) | 526.322M |
|---|---|
| Total Liabilities (in USD) | 87.483M |
| Revenue TTM (in USD) | 301.772M |
| Cash (in USD) | 107.954M |
| Market Cap (in USD) | 1,350.700 M |
| Revenue Per Share TTM | 4.294 |
| Gross Profit TTM (in USD) | 173.214M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Employees: 297
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Sanj K. Patel | CEO & Chairman | 1970 |
| 2. | Dr. John F. Paolini | Sr. VP & Chief Medical Officer | 1965 |
| 3. | Mr. Mark Ragosa C.F.A. | Sr. VP & CFO | 1975 |
| 4. | Mr. Eben Tessari | Sr. VP & COO | 1982 |
| 5. | Mr. Michael R. Megna CPA | Chief Accounting Officer & Group VP of Fin. | 1971 |
| 6. | Ms. Mei Jang | Sr. VP of Technical Operations | NA |
| 7. | Rachel Frank | Associate Director of Investor Relations | NA |
| 8. | Mr. Chad Morin | Sr. VP & Chief Compliance Officer | NA |
| 9. | Ms. Madelyn Zeylikman | SVP, Gen. Counsel & Sec. | NA |
| 10. | Ms. Melissa Manno | Sr. VP & Chief HR Officer | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.750 4.167% | 43.09 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.780 4.216% | 43.8 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+13.400 3.128% | 434.95 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+9.780 1.580% | 628.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | 11.026M | -156.539M | -156.229M | -163.914M | -103.441M |
| Minority Interest | - | - | - | - | - |
| Net Income | 183.363M | -157.924M | -161.381M | -161.867M | -103.227M |
| Selling General Administrative | 97.951M | 85.948M | 45.321M | 34.962M | 21.563M |
| Gross Profit | 173.214M | 29.444M | - | - | 0M |
| Reconciled Depreciation | 2.402M | 2.355M | 2.405M | 2.068M | 0.286M |
| Ebit | 7.371M | -158.991M | -159.768M | -172.031M | -108.446M |
| Ebitda | 9.773M | -156.636M | -157.363M | -169.963M | -108.16M |
| Depreciation And Amortization | 2.402M | 2.355M | 2.405M | 2.068M | 0.286M |
| Operating Income | 7.371M | -156.636M | -157.363M | -169.963M | -108.16M |
| Other Operating Expenses | 210.407M | 195.18M | 157.363M | 169.963M | 108.16M |
| Interest Expense | 1.253M | 2.452M | 3.539M | 8.117M | 0M |
| Tax Provision | -172.337M | 1.385M | 5.152M | -2.047M | -0.214M |
| Interest Income | 1.253M | 0.097M | 1.134M | 6.049M | 4.719M |
| Net Interest Income | 1.253M | 0.097M | 1.134M | 6.049M | 4.719M |
| Income Tax Expense | -172.337M | 1.385M | 5.152M | -2.047M | -0.214M |
| Total Revenue | 220.18M | 38.544M | 0M | 0M | 0M |
| Total Operating Expenses | 163.441M | 186.08M | 157.363M | 169.963M | 108.16M |
| Cost Of Revenue | 46.966M | 9.1M | - | - | 0M |
| Total Other Income Expense Net | 3.655M | 0.097M | 1.134M | 6.049M | 4.719M |
| Net Income From Continuing Ops | 183.363M | -157.924M | -161.381M | -161.867M | -103.227M |
| Net Income Applicable To Common Shares | 183.363M | -157.924M | -161.381M | -161.867M | -103.227M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 526.322M | 459.672M | 232.8M | 349.464M | 254.534M |
| Intangible Assets | 17.25M | 18.25M | 19.25M | - | - |
| Other Current Assets | 17.538M | 10.537M | 6.585M | 9.557M | 8.247M |
| Total Liab | 87.483M | 63.523M | 47.763M | 37.529M | 29.111M |
| Total Stockholder Equity | 438.839M | -492.034M | -675.397M | -517.473M | -356.092M |
| Other Current Liab | 52.86M | 23.866M | 1.544M | 0.037M | 0.025M |
| Common Stock | 0.02M | 0.019M | 0.018M | 0.018M | 0.015M |
| Capital Stock | 0.02M | 0.019M | 0.018M | 0.018M | 0.015M |
| Retained Earnings | -477.95M | -492.034M | -675.397M | -517.473M | -356.092M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 191.319M | 8.72M | 12.164M | 4.582M |
| Cash | 107.954M | 122.715M | 122.47M | 114.038M | 46.928M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 63.666M | 47.066M | 44.824M | 31.846M | 27.83M |
| Current Deferred Revenue | 0.307M | 12M | 38.031M | 29.199M | 20.415M |
| Net Debt | -95.696M | -116.796M | -116.42M | -107.053M | -44.276M |
| Short Term Debt | 2.253M | 3.301M | 3.381M | 2.107M | 1.697M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 12.258M | 5.919M | 6.05M | 6.985M | 2.652M |
| Other Stockholder Equity | 916.763M | -0.063M | 0.048M | 0.016M | -0.048M |
| Property Plant Equipment | - | 1.658M | 2.834M | 4.051M | 8.325M |
| Total Current Assets | 276.297M | 243.06M | 196.446M | 333.249M | 241.627M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 98.417M | 67.893M | 59.731M | 209.444M | 186.452M |
| Net Receivables | 21.266M | 20.316M | 3.985M | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | 31.122M | 21.599M | 3.675M | - | - |
| Accounts Payable | 8.246M | 7.899M | 1.868M | 0.503M | 5.693M |
| Accumulated Other Comprehensive Income | 0.006M | 0.044M | -0.066M | -0.034M | 0.033M |
| Non Currrent Assets Other | 0.827M | 5.824M | 8.72M | 5.588M | 0.21M |
| Non Current Assets Total | 250.025M | 216.612M | 36.354M | 16.215M | 12.907M |
| Capital Lease Obligations | 12.258M | 5.919M | 6.05M | 6.985M | 2.652M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -8.064M | 149.05M | -23.161M | 52.417M | -233.908M |
| Total Cashflows From Investing Activities | -8.078M | 128.635M | -23.444M | 49.214M | -239.198M |
| Total Cash From Financing Activities | 2.516M | 5.885M | 227.086M | 84.107M | 346.736M |
| Net Income | 183.363M | -157.924M | -161.381M | -161.867M | -103.227M |
| Change In Cash | 0.245M | 8.222M | 67.11M | -25.048M | 26.526M |
| Begin Period Cash Flow | 122.47M | 114.248M | 47.138M | 72.186M | 45.66M |
| End Period Cash Flow | 122.715M | 122.47M | 114.248M | 47.138M | 72.186M |
| Total Cash From Operating Activities | 5.807M | -126.298M | -136.532M | -158.369M | -81.012M |
| Depreciation | 2.402M | 2.355M | 2.405M | 2.068M | 0.286M |
| Other Cashflows From Investing Activities | 0.091M | -20M | - | 52.417M | -233.908M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -17.924M | -3.675M | -3.675M | -3.675M | -3.675M |
| Sale Purchase Of Stock | -0.901M | 5.885M | 6.553M | 84.225M | 350.393M |
| Other Cashflows From Financing Activities | -8.078M | 128.635M | -1.136M | 1.001M | 187.542M |
| Capital Expenditures | 0.105M | 20.415M | 0.283M | 3.203M | 5.29M |
| Change In Working Capital | -22.575M | 0.689M | -4.315M | -17.025M | 18.328M |
| Other Non Cash Items | 2.992M | 3.398M | 1.523M | 6.531M | -1.122M |
| Free Cash Flow | 5.702M | -146.713M | -136.815M | -161.572M | -86.302M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | SPDR® S&P Biotech ETF | 2 years ago | 1093692 |
| 2. | Pictet-Biotech P USD | 2 years ago | 980182 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 895169 |
| 4. | Vanguard Small Cap Index | 2 years ago | 765520 |
| 5. | iShares Russell 2000 ETF | 2 years ago | 740206 |
| 6. | Vanguard Small Cap Value Index Inv | 2 years ago | 516229 |
| 7. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 456230 |
| 8. | CREF Stock R1 | 2 years ago | 413640 |
| 9. | Pictet-Global Megatrend Sel I USD | 2 years ago | 412434 |
| 10. | BlackRock Advantage Small Cap Core Instl | 2 years ago | 390772 |
| 11. | Nuveen Quant Small Cap Equity R6 | 2 years ago | 332480 |
| 12. | Fidelity Small Cap Index | 2 years ago | 322348 |
| 13. | iShares Russell 2000 Value ETF | 2 years ago | 297533 |
| 14. | iShares Biotechnology ETF | 2 years ago | 289115 |
| 15. | Heptagon Driehaus US Micro Cap Eq C$ Acc | 2 years ago | 266841 |
| 16. | Meridian Small Cap Growth Legacy | 2 years ago | 217592 |
| 17. | ArrowMark Small Cap Gro | 2 years ago | 217592 |
| 18. | State St Russell Sm/Mid Cp® Indx NL Cl C | 2 years ago | 201771 |
| 19. | Goldman Sachs Small Cp Val Insghts Instl | 2 years ago | 186335 |
| 20. | Fidelity Extended Market Index | 2 years ago | 179829 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fairmount Funds Management LLC | 2 years ago | 3204841 |
| 2. | BlackRock Inc | 2 years ago | 3180588 |
| 3. | Hillhouse Capital Advisors, Ltd. | 2 years ago | 3135735 |
| 4. | Vanguard Group Inc | 2 years ago | 2981894 |
| 5. | Baker Bros Advisors LP | 2 years ago | 2809577 |
| 6. | Rubric Capital Management LP | 2 years ago | 2196009 |
| 7. | Goldman Sachs Group Inc | 2 years ago | 1818424 |
| 8. | Morgan Stanley - Brokerage Accounts | 2 years ago | 1595479 |
| 9. | State Street Corporation | 2 years ago | 1546096 |
| 10. | Pictet Asset Manangement SA | 2 years ago | 1460633 |
| 11. | BRAIDWELL LP | 2 years ago | 1392716 |
| 12. | Geode Capital Management, LLC | 2 years ago | 699613 |
| 13. | ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 2 years ago | 666976 |
| 14. | Granahan Investment Management Inc.. | 2 years ago | 648087 |
| 15. | Parkman Healthcare Partners LLC | 2 years ago | 646163 |
| 16. | Driehaus Capital Management LLC | 2 years ago | 622540 |
| 17. | Rice Hall James & Associates, LLC | 2 years ago | 618798 |
| 18. | Dimensional Fund Advisors, Inc. | 2 years ago | 506299 |
| 19. | TANG CAPITAL MANAGEMENT LLC | 2 years ago | 500000 |
| 20. | Altitude Crest Partners Inc | 2 years ago | 456041 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...